Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information

v3.23.1
Balance Sheet Information
 3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Information Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
March 31, 2023 December 31, 2022
Cash and Cash Equivalents $ 3,426,067  $ 5,964,556 
Restricted Cash, Non-current 4,185  49,260 
Total Cash, Cash Equivalents and Restricted Cash $ 3,430,252  $ 6,013,816 
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2023 December 31, 2022
Prepaid Insurance $ 28,442  $ 117,315 
Prepaid Research and Development 371,607  128,429 
Other 88,901  97,325 
Total Prepaid Expenses and Other Current Assets $ 488,950  $ 343,069 
Accrued Expenses
Accrued expenses consist of the following:
March 31, 2023 December 31, 2022
Payroll and Benefits $ 860,050  $ 1,312,443 
Professional Fees 175,972  282,721 
Clinical Trials 75,814  57,020 
Other 69,886  183,750 
Total Accrued Expenses $ 1,181,722  $ 1,835,934